000			02285 a2200613 4500
005			20250516102130.0
264		0	_c20121113
008			201211s 0 0 eng d
022			_a1476-5586
024	7		_a10.1593/neo.12328 _2doi
040			_aNLM _beng _cNLM
100	1		_aYang, Yaqiong
245	0	0	_aThe monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. _h[electronic resource]
260			_bNeoplasia (New York, N.Y.) _cJun 2012
300			_a509-18 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aAntibodies, Monoclonal _xpharmacology
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aApoptosis _xdrug effects
650	0	4	_aBenzenesulfonates _xadministration & dosage
650	0	4	_aCarcinoma, Hepatocellular _xdrug therapy
650	0	4	_aCell Line, Tumor
650	0	4	_aCell Proliferation _xdrug effects
650	0	4	_aDrug Resistance, Neoplasm _xgenetics
650	0	4	_aDrug Synergism
650	0	4	_aErbB Receptors _xantagonists & inhibitors
650	0	4	_aGene Expression Regulation, Neoplastic
650	0	4	_aHumans
650	0	4	_aLiver Neoplasms _xgenetics
650	0	4	_aMAP Kinase Signaling System _xdrug effects
650	0	4	_aMice
650	0	4	_aMice, Nude
650	0	4	_aNeovascularization, Pathologic _xdrug therapy
650	0	4	_aNiacinamide _xanalogs & derivatives
650	0	4	_aPhenylurea Compounds
650	0	4	_aProtein Kinase Inhibitors _xadministration & dosage
650	0	4	_aProto-Oncogene Proteins c-akt _xmetabolism
650	0	4	_aPyridines _xadministration & dosage
650	0	4	_aSTAT3 Transcription Factor _xmetabolism
650	0	4	_aSorafenib
650	0	4	_aXenograft Model Antitumor Assays
700	1		_aJiang, Hua
700	1		_aGao, Huiping
700	1		_aKong, Juan
700	1		_aZhang, Pengwei
700	1		_aHu, Suwen
700	1		_aShi, Bizhi
700	1		_aZhang, Pengfei
700	1		_aYao, Ming
700	1		_aLi, Zonghai
773	0		_tNeoplasia (New York, N.Y.) _gvol. 14 _gno. 6 _gp. 509-18
856	4	0	_uhttps://doi.org/10.1593/neo.12328 _zAvailable from publisher's website
999			_c21938051 _d21938051